Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / Articles / Nov / Nobel Prize for Noble Causes
Manufacture Business Practice Small Molecules Vaccines Trends & Forecasts Small Molecules

Nobel Prize for Noble Causes

The 2015 Nobel Prize in Physiology or Medicine praises advances in parasitic tropical diseases

By Stephanie Vine 11/20/2015 1 min read

Share

Tropical diseases have taken the spotlight for this year’s Nobel Prize in Physiology or Medicine. Half of the prize went to William C. Campbell and Satoshi Ōmura “for their discoveries concerning a novel therapy against infections caused by roundworm parasites”. The second half went to Youyou Tu “for her discoveries concerning a novel therapy against malaria”. All three winners are in their eighties, proving that you’re never too old to have your scientific work rewarded.

Campbell and Ōmura discovered avermectin, which has been described as having “extraordinary efficacy” against parasitic diseases. The avermectin drug family treat parasitic worms and as well as being used extensively in veterinary medicines, they have radically lowered the incidence of river blindness (onchocerciasis) and lymphatic filariasis (elephantiasis), which are both now on the verge of eradication. Avermectin has also shown efficacy against an expanding number of other parasitic diseases. Its derivative, ivermectin, is used in all parts of the world that are plagued by parasitic diseases – it has limited side effects and is freely available across the globe. The announcement of Tu as the recipient of the second half of the prize has caused a bit of a stir. Tu is credited with the discovery of artemisinin, which is highly effective against the malaria parasite, and  she is the first Chinese woman to win a Nobel Prize. Her scientific discovery was inspired by traditional Chinese medicine and her research was done exclusively in China. In the 1960s, she conducted a large-scale screen of herbal remedies in malaria-infected animals. An interesting candidate was sweet wormwood (Artemisia annua) but the results were inconsistent so Tu turned to ancient Chinese literature on herbal remedies – and eventually discovered how to successfully extract the artemisinin component.

If your own scientific work has had a humanitarian impact, then why not enter the Humanity in Science Award at: www.humanityinscienceaward.com. It’s not quite a Nobel Prize, but the winner will receive $25,000.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.